AFN-1252, a FabI inhibitor, demonstrates a staphylococcus-specific spectrum of activity

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3544-3548

  Karlowsky, James A ^a,c   Kaplan, Nachum ^b   Hafkin, Barry ^b   Hoban, Daryl J ^a   Zhanel, George G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Affinium Pharmaceuticals Inc   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFN 1252; ANTIINFECTIVE AGENT; CEFAZOLIN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECIUM; ENZYME INHIBITION; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BENZOFURANS; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENTEROBACTERIACEAE; ENTEROCOCCUS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; PYRONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

EID: 67849088246     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00400-09     Document Type: Article

References (12)

1. Campbell, J. W., and J. E. Cronan, Jr. 2001. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 55:305-332.
2. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement, M100-S17, vol. 27, no. 1. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; M7-A7, approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Reference deleted.
5. Reference deleted.
6. Heath, R. J., and C. O. Rock. 2000. A triclosan-resistant bacterial enzyme. Nature 406:145.
7. Heath, R. J., S. W. White, and C. O. Rock. 2002. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58:695-703.
8. Kaplan, N., B. Hafkin, R. Schaadt, D. Sweeney, D. Shinabarger, and G. Zurenko. 2008. Specific spectrum activity of AFN-1252 against aerobic and anaerobic bacterial pathogens, abstr. F1-341. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother.
9. Karlowsky, J. A., N. M. Laing, T. Baudry, N. Kaplan, D. Vaughan, D. J. Hoban, and G. G. Zhanel. 2007. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 51:1580-1581.
10. Payne, D. J., W. H. Miller, V. Berry, J. Brosky, W. J. Burgess, E. Chan, W. E. Wolfe, Jr., A. P. Fosberry, R. Greenwood, M. S. Head, D. A. Heerding, C. A. Janson, D. D. Jaworski, P. M. Keller, P. J. Manley, T. D. Moore, K. A. Newlander, S. Pearson, B. J. Polizzi, X. Qiu, S. F. Rittenhouse, C. Slater-Radosti, K. L. Salyers, M. A. Seefeld, M. G. Smyth, D. T. Takata, I. N. Uzinskas, K. Vaidya, N. G. Wallis, S. B. Winram, C. C. K. Yuan, and W. F. Huffman. 2002. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46:3118-3124.
11. Slater-Radosti, C., G. Van Aller, R. Greenwood, R. Nicholas, P. M. Keller, W. E. DeWolf, Jr., F. Fan, D. J. Payne, and D. D. Jaworski. 2001. Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. J. Antimicrob. Chemother. 48:1-6.
12. Weiss, W. J., B. Hafkin, N. Kaplan, M. Pulse, and P. Nguyen. 2008. Efficacy of AFN-1252 and vancomycin in the mouse subcutaneous abscess model with a methicillin-resistant S. aureus, abstr. F1-329. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother.